Grants align with World Health Organization strategy to provide screening and care for vulnerable populations and regional efforts to raise viral hepatitis prevention awareness among care providers
The Bristol-Myers
Squibb Foundation today announced nine new grants totaling more than
$3.5 million to strengthen efforts in China and India in the fight
against hepatitis B virus (HBV) and hepatitis C virus (HCV) infection by
focusing on the most vulnerable, high-risk patient populations.
The multi-year grants were made through the Foundation’s Delivering
Hope™ initiative, which has supported more than 40
projects in China and India since 2002.
These new grants align with the World Health Organization’s (WHO)
strategies for reducing the incidence of HBV and HCV infection through
early diagnosis and screening of high-risk populations, including
intravenous drug users and patients co-infected with HIV and/or
tuberculosis. Several focus on increasing awareness about disease
transmission among health care providers who care for HBV- and
HCV-infected patients, who also are considered at-risk for contracting
viral hepatitis.
Viral hepatitis is an urgent public health issue in Asia. In China and
India together, it is estimated that more than 123 million people are
infected with chronic hepatitis B and about 60 million with hepatitis C.
Although progress has been made in introducing national policies to
control the spread of HBV and HCV, community and general awareness is
considerably low. When left untreated, viral hepatitis infections result
in liver failure and chronic liver disease that can create a significant
burden on families and society.
Last year, Delivering Hope established three Centers of
Excellence, one in China and two in India, that are scaling up and
replicating achievements in hepatitis awareness, prevention and
treatment from past Foundation grantees, including several organizations
receiving new grants.
“Delivering Hope continues to increase its focus on HBV and HCV
in China and India, the two countries that have the highest incidence of
viral hepatitis worldwide,” said John Damonti, president, Bristol-Myers
Squibb Foundation. “Working with the Foundation’s Centers of Excellence
in these countries, our grantees are using successful evidence-based
practices to support the WHO’s efforts at raising awareness and
prevention of viral hepatitis among the most vulnerable and high-risk
populations, training the health care professionals who care for these
patients and increasing vaccinations and testing, all of which continue
to build health care capacity and support strong community models for
hepatitis prevention and control.”
The Foundation awarded grants for the following new projects in China:
-
Peking University Education Foundation – A virtual community
for chronic hepatitis patients will be developed to provide a support
system and enhance capacity of rural health care workers through three
functions: electronic health records, online social media and
patients’ personal reported health status. The online community will
empower patients to better self-manage their disease and provide
physicians with valuable information about how patients live with the
disease in real life.
-
Hepatitis B Foundation – Working with the Chinese Center for
Disease Control and Prevention, the Hepatitis B Foundation will
develop a program to empower rural patients to become actively
involved in their disease management and provide training for rural
doctors on hepatitis B diagnosis, transmission, prevention and disease
care and treatment.
-
Wu Jieping Medical Foundation – Based on findings from prior
programs and research funded by the Bristol-Myers Squibb Foundation,
Wu Jieping will conduct a study of the present status of HCV treatment
and the factors that influence it and will investigate HCV management
and education status among specific at-risk populations, including
those co-infected with HCV and HIV and/or tuberculosis, children and
adolescents younger than age 19, HCV patients who have cirrhosis, HCV
patients with renal insufficiency and requiring dialysis, and health
care workers who have close contact with these special populations.
-
Inno Community Development Organization – Migrant workers are a
high-risk group for HCV infection because of their low awareness of
the disease, high levels of migration and lack of access to health
care. In addition to education that will encourage self-screening and
raise awareness among migrant workers, Inno Community Development
Organization will establish 10 community-based Hepatitis C
Intervention Centers for the migrant population in Guangdong Province.
Based on the program’s success, it will serve as a model for a wider,
countrywide rollout.
The Foundation awarded grants for the following projects in India:
-
All India Institute of Diabetes and Research – A pilot program
in Mehsana and Sabarkantha, two rural districts in the state of Gujrat
that have experienced HBV outbreaks, will expand HBV testing in public
health care institutions, make vaccinations more widely available
through a network of nongovernmental organizations and hospitals, and
train health care practitioners on injection safety and universal
precautions against HBV.
-
MAMTA – Health care providers, including doctors, nurses, lab
technicians and others who come into direct contact with hepatitis
patients, will receive training in HBV and HCV risk assessment,
disease prevention and risk management. Community-based programs will
target high-risk groups, including intravenous drug user and their
partners, pregnant women and newborns. A health card will be issued to
all high-risk populations to track their navigation to comprehensive
health care services.
-
United Way of Mumbai – To help prevent disease in the
hardest-hit and most-at-risk populations, medical interventions and
extensive community education will take place in 18 slum areas in
Mumbai. The project will adopt HOPE Initiative’s Center of Excellence
School Health Program to educate students and their families about HBV
prevention and control.
-
SAMARTH – As new grantees join the Foundation’s Delivering
Hope initiative in India, proper monitoring and evaluation will
ensure that program goals are achieved. SAMARTH will conduct training
activities to strengthen partners’ ability to self-monitor and
evaluate their program’s progress and provide objective information
about program functioning, methodologies, effectiveness and impact,
and identify potential gaps.
In addition, the Foundation awarded a grant to the World Hepatitis
Alliance to develop a new model of patient group creation aimed at
physicians who treat viral hepatitis and engage them in creating and
sustaining patient support groups. These groups play a large role in
advocacy efforts that have changed health care policies and practices
for a range of diseases around the world.
The World Hepatitis Alliance will develop an e-learning tool comprised
of a video course and a text-based tool kit that will focus on the
importance of advocacy to promote viral hepatitis awareness and
prevention, the need for patient groups to be integral to advocacy,
advantages to physicians of having strong patient groups, provide
information about creating a patient group and supporting existing
groups and map out support available from the World Hepatitis Alliance
and other sources.
These learning materials will be housed on the World Hepatitis Alliance
website and will be available to be hosted on other websites, including
those operated by major international hepatology societies, to ensure
wide distribution. The project will include China and India, but is more
broadly aimed at the world.
Delivering Hope has initiated more than six patient empowerment
projects in China and India, reaching more than 6,000 patients.
About the Bristol-Myers Squibb Foundation
The mission of the Bristol-Myers Squibb Foundation is to help reduce
health disparities by strengthening community-based health care worker
capacity, integrating medical care and community-based supportive
services, and mobilizing communities in the fight against disease.
For more information about the Bristol-Myers Squibb Foundation, please
visit www.bms.com/foundation
or follow us on Twitter at http://twitter.com/bmsnews.

Media:Bristol-Myers Squibb FoundationFrederick J. Egenolf, 609-252-4875frederick.egenolf@bms.com